Results 21 to 30 of about 149,982 (260)

Timing of Early Salvage Therapy for Patients With Biochemical Relapse of Prostate Carcinoma

Oncology Reviews, 2023
Between 25% and 33% of patients after radical prostatectomy experience a relapse of the disease. The risk of relapse increases in patients with risk factors up to 50%–80%.
Soňa Argalácsová, Michal Vočka, Otakar Čapoun, Lukáš Lambert   +3 more
doaj   +1 more source

Adjuvant radiotherapy for rectal cancer

British Journal of Surgery, 2006
A hotly debated ...
K T, Moesta, F, Köckerling
openaire   +2 more sources

Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression

World Journal of Surgical Oncology, 2021
Purpose To assess the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma and to investigate subgroups of patients suitable for adjuvant radiotherapy.
Peng Wang, Haihua Zhou, Gaohua Han, Qingtao Ni, Shengbin Dai, Junxing Huang, Chunlei Dai, Lei Yu   +7 more
doaj   +1 more source

An evaluation of treatments and survival rates for pancreatic adenocarcinoma through survival analysis with inverse probability of treatment weighting: a population-based study

Journal of Pancreatology, 2021
. Objective:. This study conducted inverse probability of treatment weighting (IPTW) survival analysis to examine survival in pancreatic adenocarcinoma patients. Methods:.
Suzhen Wang, Chen Wang, Fuyan Shi, Enxue Tao, Gaopei Zhu, Juan Li, Jianing Feng, Xiaoxuan Wang, Jing Guo, Qingfeng Zheng, Bo Zhang   +10 more
doaj   +1 more source

Hypofractionation in adjuvant breast radiotherapy

The Breast, 2010
Altered fractionation for whole breast irradiation has been extensively studied over the past 20 years, with recent updated publications from several landmark randomized trials. In this review, the radiobiological principles underlying altered fractionation schedules are reviewed, and outcomes, including local control, acute and chronic toxicities from
Atif, Khan, Bruce G, Haffty
openaire   +2 more sources

Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study

BMC Cancer, 2021
Background The application of radiotherapy (RT) in pancreatic cancer remains controversial. Aim The aim of the study was to evaluate the efficacy of radiotherapy (neoadjuvant and adjuvant radiotherapy) for resectable I/II pancreatic cancer.
Dong Han, Fei Gao, Jin Long Liu, Hao Wang, Qi Fu, Guo Wang Yang   +5 more
doaj   +1 more source

Surgery, adjuvant immunotherapy plus chemotherapy and radiotherapy for primary malignant melanoma of the parotid gland (PGMM): A case report

Open Life Sciences, 2023
Primary malignant melanoma of the parotid gland (PGMM) is extremely rare, with a poor prognosis. Surgery is the main treatment option followed by adjuvant treatments such as radiotherapy, but which adjuvant treatment to be optimal is still controversial.
Zhao Qiang, Li Zhi-Ke, Gui Yan, Ma Dai-Yuan, Du Guo-Bo, Li Xian-Fu   +5 more
doaj   +1 more source

Overall Survival Benefit in Rectal Cancer After Neoadjuvant Radiotherapy and Adjuvant Chemotherapy: A Propensity-Matched Population-Based Study

Frontiers in Oncology, 2020
BackgroundIt is well known that neoadjuvant radiotherapy could reduce local recurrence followed by surgical resection. However, evidence about oncologic efficacy of radiotherapy and survival benefit of adjuvant chemotherapy after neoadjuvant radiotherapy
Zhiju Chen, Shaowei Li, Yehong Wang, Zhiming Fu, Ning Liu, Hao Wang, Xin Liu   +6 more
doaj   +1 more source

Adjuvant Versus Salvage Radiotherapy for Patients With Adverse Pathological Findings Following Radical Prostatectomy: A Decision Analysis

MDM Policy & Practice, 2017
Background: Patients undergoing surgery for prostate cancer who have adverse pathological findings experience high rates of recurrence. While there are data supporting adjuvant radiotherapy compared to a wait-and-watch strategy to reduce recurrence rates,
Christopher J. D. Wallis MD, Gerard Morton MD, Angela Jerath MD, Raj Satkunasviam MD, Ewa Szumacher MD, Sender Herschorn MD, Ronald T. Kodama MD, Girish S. Kulkarni MD, David Naimark MD, Robert K. Nam MD   +9 more
doaj   +1 more source

Central Nervous System Neuroblastoma, FOXR2‐Activated: A Pooled Analysis of Published Clinical Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) neuroblastoma, FOXR2‐activated, is a recently recognized entity in the WHO CNS5 classification, defined by activation of the FOXR2 transcription factor and unique histopathological features. This review synthesizes available literature and pooled clinical data, providing insight into demographics ...
Sudarshawn Damodharan, Mohamed S. Abdelbaki   +1 more
wiley   +1 more source